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Abstract
Introduction: Alterations in circulating large neutral amino acids (LNAAs), leading to a decrease in the plasma ratio
between branched-chain and aromatic amino acids (BCAA/AAA ratio), may be involved in sepsis-associated
encephalopathy. We hypothesised that a decrease in the BCAA/AAA ratio occurs along with a net cerebral influx of
the neurotoxic AAA phenylalanine in a human experimental model of systemic inflammation.
Methods: The BCAA/AAA ratio, the cerebral delivery, and net exchange of LNAAs and ammonia were measured
before and 1 hour after a 4-hour intravenous infusion of Escherichia coli lipopolysaccharide (LPS) in 12 healthy
young men.
Results: LPS induced systemic inflammation, reduced the BCAA/AAA ratio, increased the cerebral delivery and
unidirectional influx of phenylalanine, and abolished the net cerebral influx of the BCAAs leucine and isoleucine.
Furthermore, a net cerebral efflux of glutamine, which was independent of the cerebral net exchange of ammonia,
was present after LPS infusion.
Conclusions: Systemic inflammation may affect brain function by reducing the BCAA/AAA ratio, thereby changing
the cerebral net exchange of LNAAs.
Introduction
Sepsis-associated encephalopathy (SAE) is often one of
the first manifestations of sepsis [1] and is associated
with an adverse outcome [2,3]. The pathogenesis of SAE
is largely unknown, although several potential mechan-
isms have been investigated, including cerebral blood
flow (CBF) and metabolic alterations, intracranial hyper-
tension, cerebral edema, disruption of the blood-brain
barrier (BBB), neuronal degeneration, and abnormal
neurotransmitter composition [4].
Sepsis is characterized by increased peripheral pro-
tein breakdown, notably in skeletal muscle [5,6], and
hepatic synthesis of acute-phase reactants; the ensuing
alterations in plasma amino acids may play a key role
in SAE. Thus, the plasma ratio between branched-
chain and aromatic amino acids (BCAAs and AAAs,
respectively) decreases, because the BCAAs are
rapidly used in the liver, whereas phenylalanine levels
increase [7-9]. BCAAs and AAAs belong to the group
of large neutral amino acids (LNAAs), which compete
for the same saturable carrier across the BBB [10].
Hence, a decrease in the BCAA/AAA ratio theoreti-
cally implies either a decreased availability of BCAAs
to the brain, or an intracerebral accumulation of
AAAs, both of which may profoundly affect neuronal
function [11].
At present, neither the physiological implications of
alterations in the BCAA/AAA ratio nor the effects of
systemic inflammation on the cerebral net exchange of
LNAAs has been investigated in humans. Applying a
human experimental model of systemic inflammation,
we hypothesised that the BCAA/AAA ratio decreases
with a concurrent net cerebral influx of the neurotoxic
AAA phenylalanine, and that this attenuates the net cer-
ebral influx of BCAAs.
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Twelve healthy male volunteers aged 20 to 33 (median,
26) years participated in the study after providing oral
and written informed consent. All had an unremarkable
medical history, with no signs of infection within 4
weeks ahead of the trial day, and none took regular
medication. Before inclusion, volunteers underwent a
thorough physical examination; a 12-lead electrocardio-
gram (ECG) was obtained, and standard biochemical
tests were performed; all tests were normal. The study
was approved by the Scientific Ethical Committee of
Copenhagen and Frederiksberg Municipalities, Denmark
( f i l en u m b e r( K F )0 12 9 0 0 1 1 )a n dw a sp e r f o r m e di n
accordance with the Helsinki Declaration.
Volunteers reported to the laboratory at 7.00 a.m.
after an overnight fast and were placed in bed. They
were subsequently catheterized with antecubital cathe-
ters bilaterally (for saline and lipopolysaccharide (LPS),
respectively), a peripheral arterial line and a jugular bulb
catheter, of which the two latter were inserted by using
local anesthesia with lidocaine. The jugular bulb cathe-
ter was inserted into the right internal jugular vein with
the tip pointing cranially and by using ultrasound gui-
dance. Correct placement in the jugular bulb was ascer-
tained by feeling a resistance to further advancement of
the catheter, as well as the volunteer hearing a purl dur-
ing a bolus injection of saline; x-ray confirmation was
not used. One of the authors (KM) inserted all cathe-
ters, including the jugular bulb catheters. After catheter
insertion, the volunteer rested in the supine position
with slight head elevation for 30 minutes before mea-
surements. Heart rate (via a three-lead ECG), blood
pressure, and capillary oxygen saturation were continu-
ously monitored. Volunteers were discharged from the
unit after 12 hours after removal of catheters and a light
meal. No complications occurred.
Study design
After an overnight fast, subjects were catheterized, and
CBF measurements and paired arterio-jugular venous
blood samples were obtained at baseline and after a 4-hour
continuous intravenous infusion of purified Escherichia coli
LPS (infusion rate, 0.075 ng/kg/h; total dose, 0.3 ng/kg);
Batch G2 B274, US Pharmacopeial Convention, Rockville,
MD, USA). In this model, plasma tumor necrosis factor
(TNF)-a peaks at approximately 1 hour after cessation of
infusion [12], at which time the second CBF measurement
was performed. CBF was determined by means of the
Kety-Schmidt technique, as described elsewhere [13].
Blood gases, pH, haemoglobin, and glucose
Arterial and jugular oxygen tension (PO2), carbon diox-
ide tension (PCO2), pH, plasma glucose, and
hemoglobin were determined on a blood-gas analyser
(ABL 605, Radiometer, Brønshøj, Denmark). For the
subsequent calculation of cerebral metabolic rates
(CMRs), arterial and jugular venous PO2 and plasma
glucose were converted to whole-blood oxygen and glu-
cose content, respectively. The oxygen content (CxO2)
in arterial and jugular venous whole blood was calcu-
lated as
C O SO Hgb PO x2 2 200 1 =×+× .
in which SO2 is the oxygen-saturation fraction and Hgb
is the concentration of hemoglobin. Whole-blood glu-
cose was calculated as
Whole blood glucose plasma glucose hematoc =+ × − × 07 5 08 8 2 .( . ) ( [ r rit in %]/ ) 100
Amino acids
Because the plasma and whole-blood concentrations for
large neutral amino acids are the same in humans
[14,15] and because separation of amino acids is difficult
in whole blood, concentrations were determined in
plasma, although the exchange between brain and blood
of amino acids takes place from both plasma and red
blood cells [14,16].
Paired blood samples were simultaneously drawn from
the radial artery and the jugular vein after each CBF
measurement. The blood was immediately transferred to
chilled, heparinized glass tubes, placed on ice, and
allowed to equilibrate for 10 minutes. After this, they
were centrifuged at 4°C, 3,600 rpm, for 15 minutes. The
resultant heparinized plasma was precipitated with sul-
fosalicylic acid (6%) containing the internal standard for
the analysis, norleucine. Samples were then placed on
ice for 15 minutes, after which they were centrifuged at
4°C, 3,000 rpm for 30 minutes. With this approach, the
amino acid concentration of plasma and red blood cells
is fully equilibrated, so that the plasma concentration of
a given large neutral amino acid can be considered iden-
tical to the whole-blood concentration [17]. Accordingly,
t h ep l a s m ac o n c e n t r a t i o n so fa m i n oa c i d sa tb a s e l i n e ,
measured in the present study, were comparable to
whole-blood concentrations of amino acids in humans
reported previously [17]. The supernatant was frozen
and stored at -80°C until analysis.
LNAAs (phenylalanine, tryptophan, tyrosine, valine,
leucine, isoleucine, methionine, histidine, threonine, and
glutamine) were separated byas i n g l e - c o l u m ng r a d i e n t
lithium cation-exchange high-performance liquid chro-
matography with fluorescence detection (Waters HPLC
s y s t e m ,M i l f o r d ,M A ) ,b yu s i ng post-column derivatiza-
tion with o-phthalaldehyde-mercaptoethanol [18]. The
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is less than 5% in this setup.
Ammonia
To explicate whether a putative cerebral glutamine
efflux depended on a cerebral influx of ammonia, the
cerebral delivery and net exchange of ammonia were
evaluated. The term “ammonia” is used here to depict
the total of the charged (NH4
+) and uncharged (NH3)
species.
Immediately after each CBF measurement, paired
blood samples from the radial artery and the jugular
vein were simultaneously drawn into EDTA tubes and
placed on ice. Within 30 minutes, they were centrifuged
at 4°C, 3,600 rpm for 15 minutes; plasma was stored at
-80°C. The plasma concentration of ammonia was deter-
mined by use of microdiffusion, quantitation by reaction
with bromophenol blue, and spectrophotometry at 600
nm (Kodak Ektachem 700 Analyzer, Clinical Chemistry
Slide; Eastman Kodak Co., Rochester, NY, USA) at the
Department of Clinical Biochemistry, Rigshospitalet. In
this assay, NH4
+, which represents more than 98% of
ammonia in blood under normal physiologic conditions
[19], is directly measured. Any NH3 i nt h es a m p l ei s
converted to NH4
+ during the course of the assay; in
effect, total ammonia (NH4
+ +N H 3) is quantitated. The
range of the assay is 6 to 587 μmol/L, and internal vali-
dation revealed a coefficient of variation of 5% for values
greater than 60 μmol/L and of 11% for values less than
this. The whole-blood ammonia concentration was cal-
culated by Conn’s formula [20]:
[]
[]
.
NH
NH plasma
whole blood   =
+31
0 915
and converted from μg per 100 mL into μmol/L.
Markers of inflammation
White blood cell and platelet counts were analyzed
with standard laboratory methods. The plasma concen-
tration of TNF-a was measured by using ELISA (R&D
Systems, Minneapolis, MN, USA). Plasma was obtained
by centrifuging whole blood in EDTA-containing tubes
at 3,600 rpm at 4°C for 15 minutes and was kept at
-80°C until analysis. Samples were analyzed in dupli-
cate, and mean concentrations were calculated. Inter-
assay variability (CV) was assessed by using two
internal controls (human plasma); one in the lower
end of the standard curve ("low,” range 0.86 to 1.35
ng/L), and one in the upper end of the standard curve
("high”, range 4.32 to 5.26 ng/L), as the variability dif-
fers throughout the standard curve. Interassay CVs
were 32.9% for “low” and 12% for “high” TNF-a.T h e
TNF-a detection limit is 0.12 ng/L, according to the
manufacturer.
Calculations
The BCAA/AAA ratio was calculated as the ratio
between the arterial plasma concentrations of the
BCAAs valine, leucine and isoleucine and the AAAs
phenylalanine and tyrosine[21]:
BCAA AAA ratio
valine    leucine    isoleucine
phenyla
/
[] [ ] [ ]
[
=
++
l lanine    tyrosine ][ ]
.
+
The cerebral delivery of a given LNAA was calculated
as the product of the arterial concentration and CBF.
Cerebral net exchange (unidirectional cerebral influx -
unidirectional cerebral efflux) values of LNAAs and the
CMR of oxygen (CMRO2)a n dg l u c o s e( C M R glc)w e r e
calculated according to the Fick principle [22]:
J CBF a-jvD xx =× ,
in which Jx designates the net flux (that is, the cere-
bral net exchange or CMR) of a given substance x; a-
jvDx depicts the arterio-jugular venous concentration
difference of x in whole blood. By convention, a positive
value of Jx signifies a net influx (uptake) of x, whereas a
negative value indicates a net efflux (release) [22].
Given that the BBB transport of a substance can be
described accurately by means of a single-membrane
model in which the cerebrovascular endothelium
behaves as a single membrane, which is the case for
LNAAs [23], the unidirectional cerebral influx of pheny-
lalanine (Jin, Phe) can be calculated
J PS phenylalanine in,Phe =× 1 []
where PS1 is the permeability-surface area product of
phenylalanine from the capillary into the brain intersti-
tial space. Because the kinetic constants for the trans-
fer of phenylalanine from blood to brain have been
estimated in humans in vivo [24], and have been found
to be similar to values obtained by direct measure-
ments on human brain capillaries after death [25], PS1
can be estimated by means of the Michaelis-Menten
equation:
PS
Vmax
Km phenylalanine
KD 1 =
+
+
[]
In the present context, the maximum transport velo-
city, Vmax, was assumed to be 46.7 nmol/g/min, the
apparent Michaelis-Menten constant, Km, was assumed
to be 0.328 mmol/L, and KD, the nonsaturable diffusion
constant, was assumed to be 0.01 ml/g/min [24].
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Parametric methods were applied throughout by using
SAS statistical software, version 9.1. Thus, all analyses
were performed as paired-samples t tests, before and
after LPS infusion, to detect an effect of the interven-
tion, and between arterial and jugular venous concentra-
tions at a given time point to determine whether a
calculated cerebral net exchange value was different
from 0, that is, whether a cerebral influx or efflux was
present. Data are presented as mean (95% CI) or as geo-
metric mean (95% CI) in case data had to be log-trans-
formed to achieve normality. Significance was
established at P < 0.05.
Results
LPS infusion was associated with a pronounced inflam-
matory response; immunologic variables are summarized
in Table 1. CBF remained unchanged (baseline, 77 (55-
101) mL/100 g/min; LPS, 79 (56-109) mL/100 g/min;
NS). A mild hyperventilatory response with a decrease
in arterial PCO2 (baseline, 44.0 (42.5-45.5) mmHg; LPS,
38.8 (36.0-41.6) mmHg; P < 0.01), and an increase in
pH (baseline, 7.39 (7.38-7.40); LPS, 7.42 (7.39-7.44); P <
0.05) was evident after LPS infusion. CMRO2 increased
slightly (baseline, 1.9 (1.7-2.2) μmol/g/min; LPS, 2.3 (2.0
-2 . 6 )μmol/g/min; P <0 . 0 5 ) ,w h e r e a sC M R glc was unaf-
fected (baseline, 0.36 (0.31-0.40] μmol/g/min; LPS, 0.39
(0.34-0.44) μmol/g/min; NS). Some volunteers dozed
intermittently but remained easily rousable and alert
when awakened and were fully awake during measure-
ments; no overt signs of encephalopathy occurred.
LPS infusion increased plasma phenylalanine and
decreased the concentration of all other LNAAs except
isoleucine (Table 1), with a concurrent reduction in the
BCAA/AAA ratio (baseline, 5.2 (4.7-5.7); LPS, 4.9 (4.4-
5 . 3 ) ;F i g u r e1 ) .B o t ht h ec e r e b r a ld e l i v e r y( T a b l e2 )a n d
the unidirectional cerebral influx of phenylalanine
increased (baseline, 8.3 (6.7-9.9) nmol/g/min; LPS, 9.2
(8.9-10.4) nmol/g/min; Figure 2), whereas its cerebral
net exchange was unchanged (Table 3). Furthermore, a
net cerebral influx observed at baseline for leucine and
isoleucine was abolished after LPS infusion (Table 3). At
baseline, a net cerebral influx of methionine was pre-
sent; this was converted to a net cerebral efflux after
LPS infusion (Table 3). Furthermore, a net cerebral
efflux of glutamine that was not observed at baseline
was present after LPS infusion (Table 3). There was no
effect of LPS infusion on the arterial whole-blood con-
centration of ammonia (baseline, 78 (72-84] μmol/L;
LPS, 69 (61-76) μmol/L; NS). The cerebral net exchange
of ammonia did not differ from 0 at any time and was
unaffected by LPS infusion (baseline, 139 ([-70] - 348)
nmol/100 g/min; LPS, -98 ([-618] - 422) nmol/100 g/
min; NS).
Discussion
The present study is the first to investigate the physiolo-
gical impact of a decline in the BCAA/AAA ratio after a
standardized systemic inflammatory stimulus in humans.
In this study, systemic inflammation with an increase in
temperature, total white blood cell count, neutrophil
count, and plasma TNF-a was associated with a decline
in the BCAA/AAA ratio, mainly because of an increase
in the arterial concentration of the neurotoxic AAA
phenylalanine. A concordant increase in the cerebral
delivery and unidirectional cerebral influx of phenylala-
nine was present during systemic inflammation; this was
accompanied by an abolished net cerebral influx of the
BCAAs leucine and isoleucine, as well as a cerebral
efflux of glutamine. Assuming that the measured cere-
bral net exchange values are representative for the entire
period after LPS infusion, the present findings further-
more indicate that the brain does not contribute to the
depletion of glutamine and BCAAs from the circulation
during systemic inflammation.
A decrease in the BCAA/AAA ratio was previously
demonstrated in patients with sepsis, and this appears
to be related to the occurrence of encephalopathy [7-9].
Although the cerebral oxidative metabolism was largely
intact, and, as expected, no overt signs of SAE occurred
in the subjects, the present human experimental model
of sepsis may clarify some underlying concept in the
cerebral pathophysiology of sepsis. A decline in the
Table 1 Markers of inflammation and large neutral amino
acids
Baseline LPS
Temperature (°C) 36.3 (36.0-36.6) 38.0 (37.6-38.6)‡‡
Total white blood cells (10
9/L) 5.0 (4.5-5.5) 9.0 (8.0-10.2)‡‡
Neutrophils (10
9/L) 2.7 (2.3-3.1) 7.6 (6.6-8.7)‡‡
Lymphocytes (10
9/L) 1.5 (1.3-1.8) 0.8 (0.6-1.0)‡‡
TNF-a (ng/L) 0.9 (0.5-1.4) 10.4 (8.7-12.4)‡‡
BCAA/AAA ratio 5.2 (4.7-5.7) 4.9 (4.4-5.3)††
Phenylalanine (μmol/L) 36 (32-41) 41 (38-44)††
Tryptophan (μmol/L) 34 (31-38) 28 (25-32)††
Tyrosine (μmol/L) 41 (35-47) 34 (31-39)†
Valine (μmol/L) 224 (201-247) 200 (185-214)††
Leucine (μmol/L) 113 (101-26) 104 (95-112)†
Isoleucine (μmol/L) 59 (53-60) 57 (54-62)
Methionine (μmol/L) 14 (13-15) 9 (8-10)‡‡
Histidine (μmol/L) 74 (70-78) 58 (52-63)‡‡
Threonine (μmol/L) 102 (95-109) 74 (66-82)‡‡
Glutamine (μmol/L) 613 (556-669) 449 (411-486)‡‡
AAA = aromatic amino acid; BCAA = branched-chain amino acid, LPS =
lipopolysaccharide; TNF-a: tumor necrosis factor a. Different from baseline:
†P < 0.05; ††P <0 . 0 1 ;‡‡P < 0.0001.
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this was associated with a remarkable increase in the
estimated unidirectional influx of phenylalanine. Thus, if
it is assumed that the kinetic constants for phenylala-
nine transfer across the BBB are not affected by the LPS
challenge, the present study provides direct evidence
that links the alterations in the BCAA/AAA ratio with
changes in the brain’s amino acid content in the context
of systemic inflammation. Because we did not detect
any changes in the cerebral net exchange of phenylala-
nine, our findings furthermore imply that a new steady
state, with elevated phenylalanine levels in the cerebral
interstitial fluid, had been established before the second
measurement [23]. Previous studies demonstrated
increased cerebrospinal fluid (assumed to be representa-
tive of the cerebral interstitial fluid) levels of
phenylalanine in patients with sepsis [26], which likely
affects central noradrenergic pathways by commencing
the generation of “false” neurotransmitters, such as phe-
nylethanolamine [11,27]. An unchanged cerebral net
exchange could furthermore involve changes in BBB
function per se through a compensatory increase in the
unidirectional cerebral efflux of phenylalanine, a para-
meter that was not assessed in the present study. This
could involve the energy-dependent LNAA transporters
on the abluminal membrane of the BBB, which exports
phenylalanine from the brain [28,29].
B e c a u s eA A A sa n dB C A A sc o m p e t ef o rt r a n s p o r t
across the BBB into the brain by means of the same
saturable LNAA carrier [10], the increased arterial phe-
nylalanine levels may furthermore affect cerebral func-
tion by reducing the availability of BCAAs to the brain.
Concordant with this notion, we found that the
observed BCAA/AAA ratio decrease was associated with
Table 2 Cerebral delivery of large neutral amino acids
Amino acid Cerebral delivery μmol/
100 g/min Baseline
Cerebral delivery μmol/
100 g/min LPS
Phenylalanine 2.8 (2.4-3.2) 3.3 (2.9-3.6)†
Tryptophan 2.6 (2.3-3.0) 2.3 (1.9-2.8)
Tyrosine 3.1 (2.7-3.7) 2.8 (2.3-3.2)
Valine 17.2 (14.3-20.1) 16.2 (13.7-18.6)
Leucine 8.8 (7.1-10.4) 8.4 (7.1-9.6)
Isoleucine 4.6 (3.8-5.3) 4.7 (4.0-5.4)
Methionine 1.1 (1.0-1.2) 0.7 (0.6-0.9)‡†
Histidine 5.7 (4.9-6.5) 4.6 (4.0-5.3)†
Threonine 7.7 (6.5-9.0) 5.8 (4.9-6.9)††
Glutamine 47.3 (39.6-55.1) 36.3 (30.7-42.0)††
LPS = lipopolysaccharide. Different from baseline, †P < 0.05; ††P < 0.01;
‡†P <0.001.
Table 3 Cerebral net exchange of large neutral amino
acids
Amino acid Cerebral net exchange
nmol/100 g/min Baseline
Cerebral net exchange
nmol/100 g/min LPS
Phenylalanine 22 ([-123]-168) -17 ([-243]-210)
Tryptophan -62 ([-251]-125) -166 ([-408]-77)
Tyrosine 197 ([-67]-461) -326 ([-665]-14)
Valine 788 (116-1,460) -331 ([-1,158]-496)
Leucine 650 (263-1,037)** 159 ([-253]-571)
Isoleucine 344 (147-541)* 70 ([-161]-300)
Methionine 64 (8-12)* -42.9 ([-76]- [-9])††*
Histidine 126 ([-162]-415) -215 ([-502]-72)
Threonine 164 ([-157]-485] -355 ([-765]-56)
Glutamine -305 ([-241]-1,805) -3651 ([-6,038]- [-1,260])**
LPS = lipopolysaccharide. Different from baseline, ††P < 0.01. Cerebral net
exchange different from 0, *P <0 . 0 5 ;* * P < 0.01.
Figure 1 Branched-chain to aromatic amino acid (BCAA/AAA)
ratio after lipopolysaccharide (LPS) infusion in healthy humans.
Triangles indicate means. **Different from baseline, P < 0.01.
Figure 2 Unidirectional cerebral influx of phenylalanine (Jin,
Phe) after lipopolysaccharide (LPS) infusion in healthy humans.
Triangles indicate means. **Different from baseline, P < 0.01.
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isoleucine. Of these two BCAAs, leucine is particularly
important in the brain, in which it serves as an amino
donor for glutamate synthesis in neurons, thus ensuring
sufficiently high intracellular concentrations of gluta-
mate for neuronal glutamatergic signaling [30]; in effect,
an abolished cerebral influx of leucine may impair exci-
tatory neurotransmission. Although the available data
from previous studies are not unequivocal [31-33], it
was previously reported that restoration of the BCAA/
AAA ratio, by means of treatment with BCAA-rich solu-
tions, decreased the intracerebral levels of phenylalanine,
reinstated neurotransmitter profiles, and improved
symptoms of encephalopathy in clinical and experimen-
tal studies of sepsis [8,27,34]. The present findings may
thus corroborate conceptually important aspects of the
cerebral pathophysiology of sepsis in a human-experi-
mental setup, in which inflammation-induced alterations
in the BCAA/AAA ratio are accompanied by alterations
in the transcerebral exchange kinetics of LNAAs. Con-
versely, the observed changes could be caused by
inflammation-induced alterations in BBB function.
In the present study, LPS infusion was found to insti-
gate a decrease in the arterial glutamine levels, and a
cerebral glutamine efflux accompanied this. The former
has repeatedly been demonstrated, both in clinical and
experimental studies of sepsis [5,6,35,36]; the latter has
been described in patients with fulminant hepatic failure
[17], but has not previously been documented in sepsis.
This cerebral efflux likely reflects elevated cerebrospinal
fluid glutamine, which has been described in patients
with SAE [37].
The cerebral glutamine efflux after LPS infusion was
not found to be associated with any changes in the cere-
bral net exchange of ammonia, which is normally detox-
ified to glutamine. The classic conception that ammonia
merely diffuses across the BBB in its uncharged form
(NH3) was recently disputed [38,39]; although still con-
troversial, compelling evidence suggests that NH4
+,t h e
most abundant form of ammonia in the circulation, is
indeed transported across the BBB by means of a speci-
fic carrier [19,38]. Neither the arterial levels nor the cer-
ebral delivery of ammonia, the total of NH4
+ and NH3,
was affected in the present model. Consistent with our
findings, both circulating and brain levels of ammonia
have been reported to be unaffected by LPS infusion in
rats [40]. Hyperammonemia has, nevertheless, been
demonstrated in some animal models of sepsis [40-42]
and may aggravate intracranial hypertension in septic
rats [43]. Furthermore, the cerebral net exchange values
reported in the present study may be prone to inaccu-
racy, because of the considerable coefficient of variation
of the ammonia measurements in the lower range
(11%). Combined with the relatively low ambient
ammonia concentrations, it is possible that any minor
arterio-jugular venous concentration differences, which
could prompt significant alterations in cerebral net
exchange because of the inherently high CBF values,
were not detected in our setup. Therefore, we cannot
conclusively state that no changes in the cerebral net
exchange of ammonia were induced by LPS infusion. In
consequence, our findings do not necessarily exclude a
pivotal role of ammonia in the pathophysiology of SAE.
They do, however, suggest that any putative part played
by ammonia in this respect is more likely that of a con-
tributing than of a causative factor, and that a cerebral
ammonia uptake is not the solitary cause of the evident
cerebral glutamine efflux.
Rather than ammonia detoxification, the cerebral
efflux of glutamine after LPS infusion probably reflects
increased cerebral proteolysis or a compensatory astro-
cytic glutamine release, for example, to reduce osmotic
stress in the context of cytotoxic edema. As with pheny-
lalanine, an alternative explanation could be the pre-
sence of an inflammation-induced increase in the
activity in the energy-dependent abluminal LNAA trans-
porters [28], phenomena that are not mutually exclusive.
Glutamine supplementation was recently shown to
oppose the progressive decline in circulating glutamine
levels [35] and to attenuate organ damage in experimen-
tal sepsis [36]; however, the impact of glutamine supple-
mentation on brain function and symptoms of
encephalopathy in sepsis remains to be elucidated.
Certain limitations exist for the conclusions that can
be made from our findings. Based on the methods and
findings in the present study, we cannot definitively con-
clude that the cerebral net exchange of a given amino
acid is unaffected in sepsis. The cerebral net exchange
values are relatively small at baseline (Table 3), and the
clinical impact of LPS infusion is much less than that of
full-scale sepsis, although the two scenarios are similar
with regard to the cytokine response [44]. It is, there-
fore, possible that the immune response triggered in this
model is not sufficient to cause alterations in the cere-
bral net exchange of at least some LNAAs of a magni-
tude that can be detected by the methods applied; the
signal-to-noise ratio may be too low, and the duration
of systemic inflammation needed for the development of
such changes may be longer than that evoked by a 4-
hour LPS infusion. In addition, the Kety-Schmidt techni-
que exclusively assesses global CBF and metabolism;
consequently, potential regional changes remain
unveiled. Such changes may in reality be present both
during experimental systemic inflammation and in full-
scale sepsis. Nonetheless, an immense inflammatory
response with biochemical signs of infection was trig-
gered in the present study, and as recently reviewed, a
number of confounding factors associated with both
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the present model [44]. Hence, LPS infusion in humans
appears to be valid for human in vivo studies of certain
aspects of the pathophysiology of early sepsis.
We did not perform cognitive tests in the volunteers.
Thus, possible interrelations between cerebral function
and the described alterations in arterial amino acids
could not be assessed. It is quite possible that the gen-
eral malaise experienced by the subjects might have
affected cognitive performance, had it been tested thor-
oughly. However, because all subjects remained alert
and responsive during the course of LPS infusion, major
cognitive disturbances were unlikely to be present.
Conclusions
The present study lends further support to the view that
LNAAs, particularly phenylalanine, play a pertinent role
in the cerebral pathophysiology of sepsis; the arterial
levels, cerebral delivery, and unidirectional cerebral
influx of phenylalanine increased, whereas the cerebral
influx of leucine and isoleucine were abolished, and a
cerebral glutamine efflux was induced by LPS infusion
in humans. Future studies should address these interre-
lations and characterize them further, for example
through bedside studies on cerebral net exchange, neu-
rotransmitter profiles, BBB function, and the effects of
amino acid supplementation on brain function in
patients with sepsis.
Key messages
￿ LPS infusion induces a systemic inflammatory
response and reduces the arterial levels of most
LNAAs in humans.
￿ The systemic inflammatory response is associated
with a decrease in the BCAA/AAA ratio, because a
reduction in the arterial levels of the BCAAs valine
and isoleucine occurs with a concomitant increase in
the arterial levels of the neurotoxic AAA
phenylalanine.
￿ The BCAA/AAA ratio decrease is associated with
an increase in the cerebral delivery and unidirec-
tional cerebral influx of phenylalanine, an abolished
influx of the BCAAs leucine and isoleucine, and an
ammonia-independent cerebral efflux of glutamine.
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